Join the Aclasta group to help and get support from people like you.
Aclasta News
Zolendrate (Reclast) Lowers Fracture Risk in Early Postmenopausal Women
FRIDAY, Jan. 17, 2025 – Women past menopause can protect themselves from future fractures through infrequent, cheap IV infusions of a bone-strengthening drug. Women 50 to 60 who got two IV infusions...
Zoledronate Prevents Morphometric Vertebral Fractures Over 10 Years
WEDNESDAY, Jan. 15, 2025 – For early postmenopausal women, zoledronate administered at baseline and five years is effective for preventing morphometric vertebral fracture, according to a study...
FDA Medwatch Alert: Oral Osteoporosis Drugs (bisphosphonates): Drug Safety Communication - Potential Increased Risk of Esophageal Cancer
Includes: Fosamax (alendronate), Actonel (risedronate), Boniva (ibandronate), Atelvia (risedronate delayed release), Didronel (etidronate), and Skelid (tiludronate) ISSUE: FDA notified healthcare...
FDA Medwatch Alert: Update on Early Communication: Bisphosphonates marketed as Alendronate (Fosamax, Fosamax Plus D); Etidronate (Didronel); Ibandronate (Boniva); Pamidronate (Aredia); Risedronate (Actonel, Actonel W/Calcium); Tiludronate (Skelid); Zoledronic acid (Recl
[Posted 11/12/2008] FDA issued an update to the Agency's review of safety data regarding the potential increased risk of atrial fibrillation in patients treated with a bisphosphonate drug....
FDA Medwatch Alert: Bisphosphonates (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Reclast, Skelid, and Zometa)
[Posted 01/07/2008] FDA informed healthcare professionals and patients of the possibility of severe and sometimes incapacitating bone, joint, and/or muscle (musculoskeletal) pain in patients taking...